The role of vascular endothelial growth factor and vascular stability in diseases of the ear

Laryngoscope

Volumn 124, Issue 8, 2014, Pages

  London, Nyall R ^a   Gurgel, Richard K ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

hearing; otitis media; sensorineural hearing loss; VEGF; vestibular schwannoma

Indexed keywords

BEVACIZUMAB; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN;

ACOUSTIC NEURINOMA; ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; CAPILLARY DENSITY; DISEASE COURSE; HEARING IMPAIRMENT; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERCEPTION DEAFNESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SCALA TYMPANI; SECRETORY OTITIS MEDIA; TUMOR VOLUME; WORD RECOGNITION;

HEARING; OTITIS MEDIA; SENSORINEURAL HEARING LOSS; VEGF; VESTIBULAR SCHWANNOMA;

HEARING LOSS; HEARING LOSS, SENSORINEURAL; HUMANS; NEUROMA, ACOUSTIC; OTITIS MEDIA WITH EFFUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904725885     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.24564     Document Type: Review

References (72)

1. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF,. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
2. Nagy JA, Dvorak AM, Dvorak HF,. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2007; 2: 251-275.
3. London NR, Whitehead KJ, Li DY,. Endogenous endothelial cell signaling systems maintain vascular stability. Angiogenesis 2009; 12: 149-158.
4. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-439.
5. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-442.
6. Gerber HP, Ferrara N,. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med 2003; 81: 20-31.
7. Zachary I,. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals 2005; 14: 207-221.
8. Kim LA, D'Amore PA,. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol 2012; 181: 376-379.
9. Korpanty G, Smyth E,. Anti-VEGF strategies-from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer. Curr Pharm Des 2012; 18: 2680-2701.
10. Giacca M, Zacchigna S,. VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. Gene Ther 2012; 19: 622-629.
11. Miller C, Igarashi S, Jacob A,. Molecular pathogenesis of vestibular schwannomas: insights for the development of novel medical therapies. Otolaryngol Pol 2012; 66: 84-95.
12. Chamoun R, MacDonald J, Shelton C, Couldwell WT,. Surgical approaches for resection of vestibular schwannomas: translabyrinthine, retrosigmoid, and middle fossa approaches. Neurosurg Focus 2012; 33: E9.
13. Gurgel RK, Theodosopoulos PV, Jackler RK,. Subtotal/near-total treatment of vestibular schwannomas. Curr Opin Otolaryngol Head Neck Surg 2012; 20: 380-384.
14. Plotkin SR, Merker VL, Halpin C, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 2012; 33: 1046-1052.
15. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363: 515-521.
16. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993; 72: 791-800.
17. Labit-Bouvier C, Crebassa B, Bouvier C, et al. Clinicopathologic growth factors in vestibular schwannomas: a morphological and immunohistochemical study of 69 tumours. Acta Otolaryngol 2000; 120: 950-954.
18. Cayé-Thomasen P, Baandrup L, Jacobsen GK, Thomsen J, Stangerup SE,. Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope 2003; 113: 2129-2134.
19. Cayé-Thomasen P, Werther K, Nalla A, et al. VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 2005; 26: 98-101.
20. Koutsimpelas D, Stripf T, Heinrich UR, Mann WJ, Brieger J,. Expression of vascular endothelial growth factor and basic fibroblast growth factor in sporadic vestibular schwannomas correlates to growth characteristics. Otol Neurotol 2007; 28: 1094-1099.
21. Saito K, Kato M, Susaki N, Nagatani T, Nagasaka T, Yoshida J,. Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas. Clin Neuropathol 2003; 22: 30-34.
22. Plotkin SR, Stemmer-Rachamimov AO, Barker FG II, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009; 361: 358-367.
23. Mautner VF, Nguyen R, Kutta H, et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 2010; 12: 14-18.
24. Eminowicz GK, Raman R, Conibear J, Plowman PN,. Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy. J Laryngol Otol 2012; 126: 79-82.
25. Riina HA, Burkhardt JK, Santillan A, Bassani L, Patsalides A, Boockvar JA,. Short-term clinico-radiographic response to super-selective intra-arterial cerebral infusion of Bevacizumab for the treatment of vestibular schwannomas in Neurofibromatosis type 2. Interv Neuroradiol 2012; 18: 127-132.
26. Karajannis MA, Legault G, Hagiwara M, et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol 2012; 14: 1163-1170.
27. Wong HK, Lahdenranta J, Kamoun WS, et al. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res 2010; 70: 3483-3493.
28. Diao JS, Xia WS, Guo SZ,. Hearing improvement after bevacizumab for neurofibromatosis type 2. N Engl J Med 2009; 361: 1810; author reply 1810-1811.
29. Zhou L, Ercolano E, Ammoun S, Schmid MC, Barczyk MA, Hanemann CO,. Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways. Neoplasia 2011; 13: 1101-1112.
30. Fong B, Barkhoudarian G, Pezeshkian P, Parsa AT, Gopen Q, Yang I,. The molecular biology and novel treatments of vestibular schwannomas. J Neurosurg 2011; 115: 906-914.
31. Wong HK, Shimizu A, Kirkpatrick ND, et al. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism. Neoplasia 2012; 14: 84-94.
32. Subbiah V, Slopis J, Hong DS, et al. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. J Clin Oncol 2012; 30: e64-e68.
33. Roberts J, Hunter L, Gravel J, et al. Otitis media, hearing loss, and language learning: controversies and current research. J Dev Behav Pediatr 2004; 25: 110-122.
34. Kubba H, Pearson JP, Birchall JP,. The aetiology of otitis media with effusion: a review. Clin Otolaryngol Allied Sci 2000; 25: 181-194.
35. Skotnicka B, Hassmann E,. Proinflammatory and immunoregulatory cytokines in the middle ear effusions. Int J Pediatr Otorhinolaryngol 2008; 72: 13-17.
36. Smirnova MG, Kiselev SL, Gnuchev NV, Birchall JP, Pearson JP,. Role of the pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6 and interleukin-8 in the pathogenesis of the otitis media with effusion. Eur Cytokine Netw 2002; 13: 161-172.
37. Choi JY, Choi YS, Kim SJ, Son EJ, Choi HS, Yoon JH,. Interleukin-1beta suppresses epithelial sodium channel beta-subunit expression and ENaC-dependent fluid absorption in human middle ear epithelial cells. Eur J Pharmacol 2007; 567: 19-25.
38. Kania RE, Herman P, Tran Ba Huy P, Ar A,. Role of nitrogen in transmucosal gas exchange rate in the rat middle ear. J Appl Physiol 2006; 101: 1281-1287.
39. Ar A, Herman P, Lecain E, Wassef M, Huy PT, Kania RE,. Middle ear gas loss in inflammatory conditions: the role of mucosa thickness and blood flow. Respir Physiol Neurobiol 2007; 155: 167-176.
40. Sade J, Ar A,. Middle ear and auditory tube: middle ear clearance, gas exchange, and pressure regulation. Otolaryngol Head Neck Surg 1997; 116: 499-524.
41. Lim D, Birck H,. Ultrastructural pathology of the middle ear mucosa in serous otitis media. Ann Otol Rhinol Laryngol 1971; 80: 838-853.
42. Ryan AF, Baird A,. Growth factors during the proliferation of the middle ear mucosa. Acta Otolaryngol 1993; 113: 68-74.
43. Huang Q, Zhang Z, Zheng Y, et al. Hypoxia-inducible factor and vascular endothelial growth factor pathway for the study of hypoxia in a new model of otitis media with effusion. Audiol Neurootol 2012; 17: 349-356.
44. Jung HH, Kim MW, Lee JH, et al. Expression of vascular endothelial growth factor in otitis media. Acta Otolaryngol 1999; 119: 801-808.
45. Sekiyama K, Ohori J, Matsune S, Kurono Y,. The role of vascular endothelial growth factor in pediatric otitis media with effusion. Auris Nasus Larynx 2011; 38: 319-324.
46. Chae SW, Kim SJ, Kim JL, Jung HH,. Expression of vascular endothelial growth factor receptors in experimental otitis media in the rat. Acta Otolaryngol 2003; 123: 559-563.
47. Husseman J, Palacios SD, Rivkin AZ, Oehl H, Ryan AF,. The role of vascular endothelial growth factors and fibroblast growth factors in angiogenesis during otitis media. Audiol Neurootol 2012; 17: 148-154.
48. Kim TH, Chae SW, Kim HJ, Jung HH,. Effect of recombinant vascular endothelial growth factor on experimental otitis media with effusion. Acta Otolaryngol 2005; 125: 256-259.
49. Parkinson N, Hardisty-Hughes RE, Tateossian H, et al. Mutation at the Evi1 locus in Junbo mice causes susceptibility to otitis media. PLoS Genet 2006; 2: e149.
50. Cheeseman MT, Tyrer HE, Williams D, et al. HIF-VEGF pathways are critical for chronic otitis media in Junbo and Jeff mouse mutants. PLoS Genet 2011; 7: e1002336.
51. Hardisty-Hughes RE, Tateossian H, Morse SA, et al. A mutation in the F-box gene, Fbxo11, causes otitis media in the Jeff mouse. Hum Mol Genet 2006; 15: 3273-3279.
52. Segade F, Daly KA, Allred D, et al. Association of the FBXO11 gene with chronic otitis media with effusion and recurrent otitis media: the Minnesota COME/ROM Family Study. Arch Otolaryngol Head Neck Surg 2006; 132: 729-733.
53. Rye MS, Wiertsema SP, Scaman ES, et al. FBXO11, a regulator of the TGFβ pathway, is associated with severe otitis media in Western Australian children. Genes Immun 2011; 12: 352-359.
54. Tateossian H, Hardisty-Hughes RE, Morse S, et al. Regulation of TGF-beta signaling by Fbxo11, the gene mutated in the Jeff otitis media mouse mutant. Pathogenetics 2009; 2: 5.
55. Kamba T, McDonald DM,. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96: 1788-1795.
56. Johnson D, Sharma S,. Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration. Curr Opin Ophthalmol 2013; 24: 205-212.
57. Bodmer D,. Protection, regeneration and replacement of hair cells in the cochlea: implications for the future treatment of sensorineural hearing loss. Swiss Med Wkly 2008; 138: 708-712.
58. Heman-Ackah SE, Juhn SK, Huang TC, Wiedmann TS,. A combination antioxidant therapy prevents age-related hearing loss in C57BL/6 mice. Otolaryngol Head Neck Surg 2010; 143: 429-434.
59. Lidian A, Stenkvist-Asplund M, Linder B, Anniko M, Nordang L,. Early hearing protection by brain-derived neurotrophic factor. Acta Otolaryngol 2013; 133: 12-21.
60. Brigande JV, Heller S,. Quo vadis, hair cell regeneration? Nat Neurosci 2009; 12: 679-685.
61. Bermingham-McDonogh O, Corwin JT, Hauswirth WW, Heller S, Reed R, Reh TA,. Regenerative medicine for the special senses: restoring the inputs. J Neurosci 2012; 32: 14053-14057.
62. Hawkins JE Jr, Johnsson LG, Preston RE,. Cochlear microvasculature in normal and damaged ears. Laryngoscope 1972; 82: 1091-1104.
63. Quirk WS, Seidman MD,. Cochlear vascular changes in response to loud noise. Am J Otol 1995; 16: 322-325.
64. Shaddock LC, Hamernik RP, Axelsson A,. Effect of high intensity impulse noise on the vascular system of the chinchilla cochlea. Ann Otol Rhinol Laryngol 1985; 94 (1 pt 1): 87-92.
65. Shi X,. Cochlear pericyte responses to acoustic trauma and the involvement of hypoxia-inducible factor-1alpha and vascular endothelial growth factor. Am J Pathol 2009; 174: 1692-1704.
66. Rosenstein JM, Krum JM, Ruhrberg C,. VEGF in the nervous system. Organogenesis 2010; 6: 107-114.
67. Sondell M, Lundborg G, Kanje M,. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 1999; 19: 5731-5740.
68. Picciotti PM, Fetoni AR, Paludetti G, et al. Vascular endothelial growth factor (VEGF) expression in noise-induced hearing loss. Hear Res 2006; 214: 76-83.
69. Zou J, Pyykko I, Sutinen P, Toppila E,. Vibration induced hearing loss in guinea pig cochlea: expression of TNF-alpha and VEGF. Hear Res 2005; 202: 13-20.
70. Picciotti P, Torsello A, Wolf FI, Paludetti G, Gaetani E, Pola R,. Age-dependent modifications of expression level of VEGF and its receptors in the inner ear. Exp Gerontol 2004; 39: 1253-1258.
71. Kandasamy T, Clinkard DJ, Qian W, et al. Changes in expression of vascular endothelial growth factor and its receptors in the aging mouse cochlea, part 1: the normal-hearing mouse. J Otolaryngol Head Neck Surg 2012; 41 (suppl 1): S36-S42.
72. Monge Naldi A, Gassmann M, Bodmer D,. Erythropoietin but not VEGF has a protective effect on auditory hair cells in the inner ear. Cell Mol Life Sci 2009; 66: 3595-3599.